Immatics (IMTX)
NASDAQ:IMTX
Want to see IMTX full AI Analyst Report?
IMTX Stock Chart & Stats
$11.17
<$0.01(0.14%)
At close: 4:00 PM EST
$11.17
<$0.01(0.14%)
Day’s Range― - ―
52-Week Range$3.94 - $12.41
Previous CloseN/A
Volume408.80K
Average Volume (3M)506.26K
Market Cap
$1.49B
Enterprise Value$947.97M
Total Cash (Recent Filing)$469.14M
Total Debt (Recent Filing)$15.63M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
May 19, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.61
Shares Outstanding134,063,830
10 Day Avg. Volume297,968
30 Day Avg. Volume506,262
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.26
Price to Sales (P/S)22.65
P/FCF Ratio-6.21
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue19.64
Enterprise Value/Gross Profit19.64
Enterprise Value/Ebitda-4.91
Forecast
1Y Price Target
$20.17Price Target Upside80.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.54
Revenue Forecast (FY)$37.91M
Bulls Say, Bears Say
Bulls Say
Proprietary XPRESIDENT Discovery PlatformXPRESIDENT provides a durable, differentiated discovery engine to identify HLA-presented tumor peptides, enabling multiple matched TCR and bispecific programs. A robust platform increases hit rates, supports sustained pipeline generation, and creates licensing/partnering leverage over years.
Strong Balance Sheet And RunwayLow leverage and >$550M in cash provide material financial flexibility to fund pivotal readouts and initial commercialization work toward a potential 2027 launch. This reduces near-term refinancing risk and supports continued clinical development and strategic optionality across programs.
Clinical And Regulatory Momentum (PRAME Franchise)Progress toward a global Phase 3 readout, regulatory designations, planned BLA timing and high-profile ASCO oral presentations signal durable clinical/regulatory advancement. These milestones strengthen first-to-market positioning for PRAME-targeted therapies and broaden long-term commercial potential.
Bears Say
Sustained Negative Operating Cash FlowNegative operating and free cash flow in 2024–2025 indicate ongoing cash burn despite prior positive years. Over a multi-quarter horizon this weakens self-funding ability for late‑stage work, increases reliance on capital raises, and raises dilution and execution risk before commercialization.
Volatile Profitability And 2025 DeteriorationEarnings and revenue have been inconsistent across years, culminating in a sharp 2025 loss. This volatility signals execution and commercialization uncertainty, complicates forecasting, and pressures margin sustainability even if clinical readouts succeed.
Revenue Model Dependent On CollaborationsAs a clinical-stage biotech, near-term revenue depends on partner deals, milestones and potential future royalties rather than product sales. This creates revenue timing risk and exposure to partner decisions, which can materially affect funding and program advancement over many quarters.
Immatics News
IMTX FAQ
What was Immatics’s price range in the past 12 months?
Immatics lowest stock price was $3.94 and its highest was $12.41 in the past 12 months.
What is Immatics’s market cap?
Immatics’s market cap is $1.49B.
When is Immatics’s upcoming earnings report date?
Immatics’s upcoming earnings report date is May 19, 2026 which is in 14 days.
How were Immatics’s earnings last quarter?
Immatics released its earnings results on Mar 05, 2026. The company reported -$0.327 earnings per share for the quarter, beating the consensus estimate of -$0.481 by $0.154.
Is Immatics overvalued?
According to Wall Street analysts Immatics’s price is currently Undervalued.
Does Immatics pay dividends?
Immatics does not currently pay dividends.
What is Immatics’s EPS estimate?
Immatics’s EPS estimate is -0.46.
How many shares outstanding does Immatics have?
Immatics has 134,063,830 shares outstanding.
What happened to Immatics’s price movement after its last earnings report?
Immatics reported an EPS of -$0.327 in its last earnings report, beating expectations of -$0.481. Following the earnings report the stock price went down -0.295%.
Which hedge fund is a major shareholder of Immatics?
Currently, no hedge funds are holding shares in IMTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immatics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.17 (80.54% Upside)
$20.17 (80.54% Upside)
Blogger Sentiment
Bullish
IMTX Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 178.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 16.7%
Last 30 Days ▲ 16.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
162.20%
12-Months-Change
Fundamentals
Return on Equity
-39.69%
Trailing 12-Months
Asset Growth
-8.38%
Trailing 12-Months
Company Description
Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
IMTX Stock 12 Month Forecast
Average Price Target
$20.17
▲(80.54% Upside)
Technical Analysis
Ownership Overview
―
Insiders
10.93% Mutual Funds
0.58% Other Institutional Investors
87.84% Public Companies and
Individual Investors